SIETES :: 93212 citas

Resultados de la búsqueda por ANTICUERPOS ANTI-TNF REFINAR BÚSQUEDA

21.

Andersen NN, Pasternak B, Friis-Moller N, Andersson M, Jess T. Association between tumour necrosis factor-a inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015;350:h2809. [Ref.ID 99191]

22.

van Herwaarden N, van der Maas A, Minten MJM, van den hoogen FHJ, Kievit W, van Vollenhoven RF, Bijlsma JW, van den Bemt BJF, den Broeder AA. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350:h1389. [Ref.ID 98963]

23.

Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M, Patel A, Kingsley GH. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015;350:h1046. [Ref.ID 98857]

24.

Anónimo. Tocilizumab et arthrite juvénile idiopathique polyarticulaire. Pas mieux que les anti-TNF alpha. Prescrire 2014;34:741-2. [Ref.ID 98262]

25.

Anónimo. Golimumab et rectocolite hémorragique. Un autre anti-TNF, alpha, sans plus. Prescrire 2014;34:738. [Ref.ID 98259]

26.

Anónimo. Ustékinumab et rhumatisme psoriasique. Prescrire 2014;34:412. [Ref.ID 97943]

27.

Anónimo. Golimumab (Simponi) for ulcerative colitis. Med Lett Drugs Ther 2014;56:25-6. [Ref.ID 97521]

28.

Díaz Cuevas Z, Rodríquez Lozano B, Campos Gutierrez S, Lecuona Fernández M. Lesiones cutáneas nodulares en paciente con artritis reumatoide en tratamiento con anti-factor de necrosis tumoral-alfa.. Med Clin (Barc) 2014;142:183-4. [Ref.ID 97319]

29.

Anónimo. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis. Med Lett Drugs Ther 2014;56:10-2. [Ref.ID 97221]

30.

Anónimo. adalimumab (Humira) et enfants atteints de maladie de Crohn sévère. Autant d'incertitudes qu'avec l'infliximab. Prescrire 2014;34:98. [Ref.ID 97124]

31.

Simon PC, Vallano A. Fármacos que inhiben el factor de necrosis tumoral alfa y embarazo. Med Clin (Barc) 2013;141:257-9. [Ref.ID 96078]

32.

33.

Anónimo. Adalimumab et spondylarthrite axiale. Prescrire 2013;33:497. [Ref.ID 95939]

34.

Anónimo. Golimumab approved for ulcerative colitis. WHO Drug Information 2013;27:115. [Ref.ID 95814]

35.

Bathon JM, McMahon DJ. Making rational treatment decisions in rheumatoid arthritis when methotrexate fails. N Engl J Med 2013;369:384-5. [Ref.ID 95655]

36.

Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419-25. [Ref.ID 95639]

37.

Anónimo. FDA approves Simponi to treat ulcerative colitis . U.S. Food and Drug Administration 2013:15 de mayo. [Ref.ID 95446]

38.

39.

Anónimo. Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013;55:1-3. [Ref.ID 94735]

40.

Sandborg C, Mellins ED. A new era in the treatment of systematic juvenile idiopathic arthritis. N Engl J Med 2012;367:2439-40. [Ref.ID 94270]